Devimistat

Phase 2Small molecule

NNorthwestern University

Devimistat is one of 29 small molecule programs targeting Refractory Solid Tumors. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Refractory Solid TumorsRecruiting

Refractory Solid TumorsPhase 2

Recruiting

Competition

Competitive Landscape

35 competitors in Refractory Solid Tumors

#DrugCompanyPhaseTrials

Camptosar

Pfizer

Phase 2

7 2

Votrient

Novartis

Phase 2

5 3

Oncovin

Eli Lilly

Phase 2

4 4

Opdivo

Bristol-Myers Squibb

Phase 2

3 5

Keytruda

Merck & Co.

Phase 2

3 6

Gemzar

Johnson & Johnson

Phase 2

2 7

Ibrance

Pfizer

Phase 2

1 8

Tecentriq

Roche

Phase 2

1 9

Plaquenil

Jazz Pharmaceuticals

Phase 2

1 10

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2030

Phase 2Recruiting

Refractory Solid Tumors

NCT05733000

Clinical

Trials by Indication[1]

Refractory Solid Tumors1 trial

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors

Recruiting·NNorthwestern University·Phase 2·NCT05733000·94 enrolled

Adenocarcinoma1 trial

Trial of Devimistat in Combination With Modified FOLFIRINOX in Patients With Metastatic Adenocarcinoma of the Pancreas

Withdrawn·UUniversity of Michigan Rogel Cancer Center·Phase 1/2·NCT05926206

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Devimistat. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Devimistat compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Devimistat. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Northwestern University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNorthwestern University

Devimistat

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2030

Trials by Indication[1]

Refractory Solid Tumors1 trial

Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News